John A. Sedor, Chairman & CEO
John is a 30-year veteran of the pharmaceutical industry with a track record of creating value for shareholders at public and private companies.
Cangene: $220 million Sale of the Company
President, CEO, Board Member, Cangene Corporation (formerly TSX: CNJ)
2011 – 2014
Transformed Cangene from a biodefense developer/government contractor to a specialty pharmaceutical company
Divested non-core assets
Aligned manufacturing, marketing, and sales force across North America
Acquired Hemophelia assets from Ipsen
Acquired by Emergent BioSolutions in 2014 for $220 million, a 45% premium
Bentley: $375 million Sale of the Company
President, CEO, Bentley Pharmaceuticals (formerly NYSE: BNT) 2005-2008
Expanded nanotechnology programs,
lead the launch of more than 20 new product in the EU
Acquired by Teva Pharmaceutical Industries in 2008 for $375 million
CPEX: $75 million Sale of the Company
Chief Executive Officer, President and Director, CPEX Pharmaceuticals (formerly NASDAQ: CPEX) 2009-2011
Orchestrated the spin-off of CPEX from Bentley as part of the transaction with Teva
Led development/commercialization of patented drug delivery technology
Sold to Footstar in 2011 for $75 million
Sandoz (division of Novartis AG): Increased U.S. Sales to $1.2 Billion
President, Sandoz Inc. 2001–2005
Led efforts to more than double net sales growth and overall profitability
Previously, Mr. Sedor served as President and Chief Executive Officer at Centeon, LLC, a joint venture between two major multinational corporations, Rhône-Poulenc Rorer and Hoechst AG. Previously, Mr. Sedor served as Executive Vice President at Rhône-Poulenc Rorer, Revlon Health Care and Parke-Davis. Mr. Sedor holds a Bachelor of Science degree in Pharmacy/Chemistry from Duquesne University, and has studied strategic marketing at both Northwestern University’s Kellogg Graduate School of Management and Harvard Business School. He has also attended Harvard’s Executive Forum.
Currently, Mr. Sedor is a Board Member, Pernix Therapeutics (NASDAQ: PTX), a specialty pharmaceutical company primarily focused on the sales, marketing, and development of branded pharmaceutical products. He also serves on the Board of Directors for Velico Medical Inc, a clinical-stage company developing product-candidates for blood transfusions safety.
Gary C. Floyd, Chief Operating Officer
Gary is a seasoned pharmaceutical executive with over 40 years’ experience in the manufacture, sales and development of drugs and biologicals.
Armour Pharmaceutical Company
Plant Manager and Vice President of Operations of their 500,000 sq. ft. manufacturing plant that produced Small Volume and Large Volume sterile liquids, plasma proteins, oral drugs and inhalation products using form-fill-seal technology. In addition, he was Vice President of Marketing and Sales at Armour for North and South America.
Senior Vice President of Global Operations for Centeon, a combined Plasma Products company of Armour Pharmaceutical Company and Behringwerke, AG.
Senior Vice President of Worldwide Logistics
Eximias Pharmaceuticals/YM Biosciences
In 2004, he joined Eximias Pharmaceuticals as head of Clinical Operations, Manufacturing and Quality Control. Eximias later merged with YM Biosciences where he was Vice President of Operations and led manufacturing development, Quality Assurance and Assay Development.
Chief Operating Officer of Cangene Corporation from 2012 to 2014 where he was responsible for regulatory compliance, quality assurance, manufacturing, analytical testing and development, project management and government contracting. He also served as the Chief Compliance Officer for the company.
Gary has a bachelor degree in Zoology and Chemistry from Olivet Nazarene University and has attended continuing education programs including Finance at University of Pennsylvania, Strategic Marketing at both Stanford and Harvard University and a Pharmacy program at the University of Tennessee.
Member, American Association of Pharmaceutical Scientists